Life Sciences

  • September 23, 2016

    GSK Still Wants Hearing On Expert Of Reed Smith Atty's Widow

    GlaxoSmithKline PLC on Thursday urged an Illinois federal court not to call off a pretrial hearing to vet the mental health expert of a widow of a Reed Smith LLP partner who killed himself after taking the company's antidepressant, saying it is making a legitimate request for information.

  • September 23, 2016

    Mylan Asks High Court To Rule On Venue For ANDA Cases

    The conduct by defendants up to the time a lawsuit is filed, not speculation about what they may do in the future, should dictate the proper venue for where patent infringement suits under the Hatch-Waxman Act may be filed, generics maker Mylan Inc. has told the U.S. Supreme Court in a closely watched case concerning jurisdiction.

  • September 23, 2016

    3 Firms Prime IPOs Totaling $547M Led By 'Unicorn' Nutanix

    Three firms will guide initial public offerings estimated to total $547 million during the final week of September, highlighted by Silicon Valley technology startup Nutanix that would mark the second so-called unicorn to go public in 2016, plus a real estate investment trust and two biotechs.

  • September 23, 2016

    High Court Asked To Nix PTAB Power To Start AIA Reviews

    Ethicon has urged the U.S. Supreme Court to hear its challenge of the Patent Trial and Appeal Board’s practice of having the same panel that opens an America Invents Act review decide it, arguing it contradicts the law that created the review process.

  • September 23, 2016

    2nd Circ. Says CoreLogic Doesn't Have To Pay $4M In FTC Suit

    The Second Circuit on Friday upheld a lower court’s ruling that LeadClick Media LLC violated the Federal Trade Commission Act through its role in a deceptive marketing scheme for weight-loss products but differed in finding that parent company CoreLogic wasn’t required to pay out $4.1 million.

  • September 23, 2016

    FDA Approves Amgen's Humira Biosimilar

    The U.S. Food and Drug Administration on Friday approved Amgen Inc.’s Amjevita, a biosimilar of AbbVie Inc.’s immunosuppressant Humira — the world’s best-selling drug — for which the two companies are already caught up in patent infringement litigation.

  • September 23, 2016

    Health Hires: BakerHostetler, Hinckley Allen, Ballard Spahr

    BakerHostetler has added a life sciences litigator from Fish & Richardson PC to its intellectual property group, Hinckley Allen & Snyder LLP has brought on a veteran federal prosecutor, and Ballard Spahr LLP has rehired a former associate who spent the last two years at University of Pennsylvania-run hospitals as counsel on privacy matters.

  • September 23, 2016

    Rainmaker Q&A: Hogan Lovells' Alice Valder Curran

    I have built much of my success on a relatively straightforward concept: What would my clients be interested in hearing about and how can I relay that information in a way that would be most useful? If you accept that challenge, you elevate your relationship from outside counsel to business partner, and clients know the difference, says Alice Valder Curran, global head of the government regulatory practice at Hogan Lovells.

  • September 22, 2016

    J&J Invokana Suits Should Be An MDL, Patients Say

    Patients suing Johnson & Johnson over harm to their kidneys allegedly caused by the company's Invokana diabetes drug asked the Judicial Panel on Multidistrict Litigation on Thursday to consolidate 56 individual actions in New Jersey federal court.

  • September 22, 2016

    Generic EpiPen Will Likely Secure Profits For Mylan

    Mylan NV's planned introduction of a generic EpiPen is less likely an act of repentance after overcharging customers for a lifesaving drug and more a calculated move to secure loyalty ahead of competitors' entry to the market, as well as a means of cutting out middlemen who take a share of the profits, experts said Thursday.

  • September 22, 2016

    FCC Fines Siemens $175K For Hiding FCPA Felonies

    Siemens Co. and Siemens Medical Solutions USA Inc. have agreed to pay a $175,000 fine to resolve a Federal Communications Commission investigation into their wireless license applications, which allegedly fail to disclose past felony convictions for bribing foreign officials, the FCC said Thursday.

  • September 22, 2016

    Drug Cos. Tell 3rd Circ. To Affirm Eye Drop Suit Dismissal

    Pfizer, Merck and others urged the Third Circuit on Wednesday not to revive litigation accusing the drugmakers of boosting prescription eye drop sales by using bottles that dispensed bigger-than-needed drops, contending that a lower court correctly found the patients didn't show sufficient injury.

  • September 22, 2016

    Seniors Urge 9th Circ. To Revive Suit Over Muscle Drink

    Senior citizens who contend Abbott Laboratories Inc. duped them into paying the equivalent of $32 a gallon for Ensure Muscle Health shakes that they say are basically just chocolate milk told the Ninth Circuit that a lower court wrongly dismissed their claims.

  • September 22, 2016

    35 States Sue Indivior In Antitrust Row Over Suboxone

    Top prosecutors for New York and Pennsylvania said Thursday they have joined forces with 33 other states to lodge an antitrust suit against Indivior in Pennsylvania federal court, alleging that the British drugmaker is unlawfully attempting to keep a generic version of opiate addiction treatment Suboxone off the market.

  • September 22, 2016

    Medtronic Avoids Off-Label Spinal Fusion Device Suit

    A federal judge in Ohio on Thursday dismissed a suit accusing medical equipment company Medtronic of teaming up with a now-fugitive Cincinnati doctor to hawk a dangerous spinal surgery device off-label.

  • September 22, 2016

    Costco Fights 9th Circ. Appeal Over Apotex Drug's Origins

    Costco asked the Ninth Circuit on Wednesday to reject the appeal of a man suing over the country of origin of generic Lipitor obtained at the warehouse chain's pharmacy, saying the man didn't even read the bottle he supposedly relied on for origin information.

  • September 22, 2016

    GSK Exec Can't Dodge Whistleblower's Firing Suit

    A GlaxoSmithKline executive lost his bid to toss an employee’s whistleblower lawsuit Thursday when a New Jersey federal judge ruled that the United Kingdom resident was properly served the complaint under European law.

  • September 22, 2016

    Bayer Willing To Give Up $1.6B Yearly To Land Monsanto

    Chemical and drug heavyweight Bayer has committed to selling off parts that net it up to $1.6 billion in sales per year to complete its merger with crop giant Monsanto if regulators demand it as a condition of the deal, Monsanto said in a Wednesday filing.

  • September 22, 2016

    Senate GOP Pushes Gov't Funding Band-Aid, As Dems Balk

    Republican leadership in the Senate introduced Thursday their proposal to keep the government running after Sept. 30, even as disputes with Democrats over aid for Flint, Michigan, threatens to pull it apart.

  • September 22, 2016

    Fed. Circ. Affirms J&J Win In Roche Blood Test Patent Case

    The Federal Circuit on Thursday upheld a lower court’s decision that a Johnson & Johnson unit does not infringe a Hoffmann-La Roche unit’s blood test patents in a lengthy dispute that hinged on the meaning of a single claim term.

Expert Analysis

  • Practical Uses For Machine Learning In Health Care Cases

    Mihran Yenikomshian

    Machine learning can efficiently turn enormous volumes of both structured and unstructured data into something meaningful, without losing underlying details. Consultants with Analysis Group Inc. elaborate on how machine learning can be applied in the courtroom in terms of informing legal strategy, identifying relevant materials for experts, and enhancing expert testimony in health care litigation.

  • Overhauling Law Firm Records Departments For A New Reality

    Raymond Fashola

    As automation increases, so do business challenges that impact overall law firm operations. Records departments are facing roadblocks associated with antiquated processes, ever-changing regulatory requirements, and emerging technologies. As a result, firms are reassessing the needs of their records department staffing models, says Raymond Fashola of HBR Consulting.

  • The Potential For Litigation In New Era Of Biosimilars

    Christian Frois

    In recent years, there has been widespread litigation surrounding generic entry across a wide range of therapeutic classes. As biosimilars are now becoming available in the U.S., should we expect similar litigation? The answer is not that simple given the economics of biosimilars as well as some key differences between biologic and chemical drugs, say Christian Frois, Richard Mortimer and Alan White of Analysis Group Inc.

  • In Congress: A Continuing Resolution?

    Richard Hertling

    The finish line for Congress could come this week as House and Senate leaders negotiate a continuing resolution to keep the government running into December, though major points of contention over possible provisions were still unresolved as of Friday evening, say Richard Hertling and Kaitlyn McClure of Covington & Burling LLP.

  • Evidence Of Copying Is Irrelevant In Hatch-Waxman Cases

    Jonathan Bachand

    A Delaware federal court's recent decision in Bayer v. Watson may revive efforts by branded drug manufacturers to convince courts in Hatch-Waxman litigation to consider evidence of copying as an indication that a patent at issue is not obvious. However, it should never be considered by courts because the relevant statutes anticipate and incentivize the copying, say Jonathan Bachand and Ashley Morales of Knobbe Martens Olson & Bear LLP.

  • Sen. Leahy On The AIA's 5th Anniversary

    Sen. Patrick Leahy

    Enactment of the America Invents Act was more than a victory for American inventors; it was a demonstration that Congress could still work in a bipartisan, bicameral manner. It showed what we can achieve when we put aside rhetoric and negotiate in good faith, says Sen. Patrick Leahy, D-Vt.

  • Rep. Smith On The AIA's 5th Anniversary

    Rep. Lamar Smith

    While the primary purpose of the America Invents Act was to improve the validity of the patent-granting process, the legislation included a narrow provision to improve patent litigation. Unfortunately, some activist judges have ignored this new tool, says Rep. Lamar Smith, R-Texas.

  • From Fapiao To Gestores: FCPA Risks In China, Latin America

    Saskia Zandieh

    A review of Foreign Corrupt Practices Act matters and corruption scandals involving China and Latin America reveals specific risks areas companies should address when tailoring their compliance programs, say Saskia Zandieh and Alice Hsieh of Miller & Chevalier Chtd.

  • 3 Steps To Successful Judgment Enforcement

    Craig Weiner

    Judgment enforcement is typically governed by the law of the state where collection is sought, which frequently means collection efforts are controlled by an arcane body of law replete with debtor-friendly roadblocks. Fortunately, there are a number of actions a judgment creditor can take to secure satisfaction of a claim, say Craig Weiner and Michael Kolcun of Robins Kaplan LLP.

  • The Post-AIA Battleground For Patent Challenges

    Robert Greene Sterne

    The implementation of the America Invents Act, which began on Sept. 16, 2012, ushered in a new age for patent law. The impact of the AIA has reverberated across all technological sectors and fundamentally changed the way the patent community approaches prosecution, licensing, enforcement and monetization, say attorneys with Sterne Kessler Goldstein & Fox PLLC.